Genalyte Finger Prick Test Can Rapidly & Affordably Detect Ebola Virus at Early Stage
High Volume Testing Platform Can be Deployed Cost-Effectively to Front-Lines
(New York, NY) – San Diego based diagnostic laboratory start-up Genalyte has developed a new test capable of detecting the presence of Ebola in the blood in the early stages of the virus. Genalyte’s test has significantly outperformed other rapid tests currently available in terms of speed, accuracy, testing volume and cost, providing the most effective and efficient means to detect the virus, treat patients, and save lives.
The Genalyte test, which is performed on the company’s commercially available platform, is processed with a single drop of blood from a finger prick and offers results in as little as 10 minutes. Genalyte’s silicon chip technology offers a new platform for testing that fills a key gap in the diagnostics market—offering the high accuracy and sensitivity of gold standard testing mechanisms, with the diagnostic speed, high volume testing capacity, and low cost of other rapid tests. Additionally, Genalyte’s technology, which can process as many as 100 tests per hour, can be deployed to hospitals and airports as well as to the front lines in West Africa, where many victims are currently not being tested.
“Working together with the FDA, CDC, policymakers and health organizations we are committed to expediting the necessary protocols and distributing our tests to all those in need,” said Genalyte Founder and CEO Cary Gunn. “With FDA authorization, our Genalyte team can deploy tests immediately to help detect the virus sooner, stop the spread of the disease, and facilitate more timely treatment of those infected.”
Genalyte sets itself apart from other tests under evaluation in four key ways:
• Know Sooner, Faster: Genalyte is built for the highly sensitive detection of Ebola virus antigens and IgM and IgG antibodies against Ebola. This enables the detection of Ebola virus at an early stage. The test takes approximately 10 minutes, which allows for rapid results and immediate treatment for all those who test positive. • More Accurate, Higher Sensitivity Rapid Testing: Genalyte’s test has outperformed other rapid tests on the market, demonstrating better accuracy and higher sensitivity (including the ELISA test and lateral flow technology testing). In combination, these factors should allow for the detection of the Ebola virus in the blood days earlier than any current test.
• Faster Screening: Able to process nearly 100 people per hour, Genalyte’s testing enables rapid screening of large groups of people (such as medical staff, or passengers on a plane) at one time. Genalyte offers high volume, rapid testing technology like none other.
• Technology ready today: Genalyte’s testing platform is commercially available today, and validation of the Ebola tests is only weeks away. We can make a difference in the near future where it counts most.
Early detection is the missing link needed to bring the Ebola epidemic under control. Genalyte hopes to work with the U.S. government to make its platform available to all those who need a better diagnostic solution here and abroad.
###
MEDIA ALERT: Any press interested in speaking with Genalyte CEO Cary Gunn, please contact media@genalyte.com, or Erin Pelton, Jennifer Wlach & Eve Zibel at 212-681-1380
CONTACT: media@genalyte.com
Help employers find you! Check out all the jobs and post your resume.
